Wordt geladen...
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
We screened TP53 mutations in 168 MDS patients who were treated with HMA and evaluated predictive and prognostic value of TP53 mutations. Overall response to HMA was not different based on TP53 mutation status (45% vs. 32% in TP53-mutated and wild type [WT], respectively, P = 0.13). However, respons...
Bewaard in:
| Gepubliceerd in: | Oncotarget |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Impact Journals LLC
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4924706/ https://ncbi.nlm.nih.gov/pubmed/26871476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7290 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|